<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02493660</url>
  </required_header>
  <id_info>
    <org_study_id>CLD-OR-010</org_study_id>
    <nct_id>NCT02493660</nct_id>
  </id_info>
  <brief_title>A Pivotal Study to Assess the InSpace™ Device for Treatment of Full Thickness Massive Rotator Cuff Tears</brief_title>
  <official_title>A Prospective, Single Blinded, Multi-center, Randomized, Controlled, Pivotal Study to Assess the Safety and Effectiveness of the InSpace™ Device for Treatment of Full Thickness Massive Rotator Cuff Tears</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrthoSpace Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OrthoSpace Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pivotal study to assess the safety and effectiveness of the InSpace™ device implantation in&#xD;
      comparison to surgical partial repair of full thickness Massive Rotator Cuff Tear (MRCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-inferiority, prospective, single blinded, multi-center, randomized, controlled,&#xD;
      pivotal study evaluating the safety and effectiveness of the InSpace™ device as a primary&#xD;
      surgical treatment for full thickness MRCT in comparison to Partial Repair of a full&#xD;
      thickness MRCT performed during an arthroscopic procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2015</start_date>
  <completion_date type="Actual">March 17, 2020</completion_date>
  <primary_completion_date type="Actual">February 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in the Intent to Treat Population (ITT) With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears (MRCT).</measure>
    <time_frame>Through to M12 post operation.</time_frame>
    <description>The primary composite effectiveness endpoint was defined as achievement of the minimal clinically important difference (MCID) improvement for the Western Ontario Rotator Cuff (WORC) score (≥275 points) and American Shoulder and Elbow Society (ASES) score (≥6.4 points) by week 6 and maintenance at month 12 without subsequent secondary surgical intervention (SSSI) or serious adverse device effects (SADEs).&#xD;
The improvement points of Western Ontario Rotator Cuff (WORC) of at least 275 (point scale of 0-2100:lower score is better) and American Shoulder and Elbow Society (ASES) at least 6.4 (point scale of 0-100:higher score is better) reflect the required number of points in improvement for treatment to be considered successful.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears From Baseline Through to Month 12 With no SSSIs and no SADEs.</measure>
    <time_frame>Through to M12 post operation</time_frame>
    <description>The secondary composite effectiveness endpoint was defined as achievement of the minimal clinically important difference (MCID) success rates for Western Ontario Rotator Cuff (WORC) total score improvement (≥275) (0-2100:lower score is better) and American Shoulder and Elbow Surgeons (ASES) total score improvement (≥6.4) (0-100:higher score is better) from baseline in the two groups, InSpace and Partial Repair.&#xD;
The Intent to Treat (ITT) population, defined as all randomized subjects with at least one post-treatment effectiveness assessment as randomized, was used as the primary population and to generate all other effectiveness endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Month 12 in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears.</measure>
    <time_frame>Through to M12 post operation</time_frame>
    <description>The secondary effectiveness endpoint was defined as mean change from baseline to Month 12 for American Shoulder and Elbow Surgeons (ASES) total score improvement (≥ 6.4) (scale of 0-100:higher score is better) from baseline in the two groups, InSpace and Partial Repair.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Month 12 in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears Through to Month 12.</measure>
    <time_frame>Through to M12 post operation</time_frame>
    <description>The secondary effectiveness endpoint was defined as mean change from baseline to Month 12 for Western Ontario Rotator Cuff (WORC) total score improvement (≥275) (scale of 0-2100:lower score is better) in the two groups, InSpace and Partial Repair.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Month 12 in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears From Baseline Through to Month 12.</measure>
    <time_frame>Through to M12 post operation</time_frame>
    <description>The secondary effectiveness endpoint was defined as change from baseline to Month 12 for Constant-Murley (CS) Shoulder Outcome score (scale of 0-100:higher score better) in the two groups, InSpace and Partial Repair.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change From Baseline for the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears From Baseline Through to Month 12.</measure>
    <time_frame>Through to M12 post operation</time_frame>
    <description>The secondary effectiveness endpoint was defined as change in baseline to Month 12 for Quality of Life (EQ-5D-5L) (scale of 0-100: lower score better) in the two groups, InSpace and Partial Repair.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears Through to Month 12.</measure>
    <time_frame>Through to M12 post operation</time_frame>
    <description>The secondary effectiveness endpoint was defined as the mean change from baseline at Month 12 for Visual Analogue Scale (VAS) (scale of 0-100:lower score is better) in the two groups, InSpace and Partial Repair.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears Through to Month 12.</measure>
    <time_frame>Through to M12 post operation</time_frame>
    <description>The secondary effectiveness endpoint was defined as mean change from baseline at Month 12 for American Shoulder and Elbow Surgeons (ASES) range of motion (ROM)-physician reported portion. (scale of 0-180 Degrees: higher score is better) in the two groups, InSpace and Partial Repair.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Rotator Cuff Syndrome</condition>
  <arm_group>
    <arm_group_label>InSpace implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tendon Repair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arthroscopic partial repair of rotator cuff</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InSpace sub-acromial tissue spacer system</intervention_name>
    <description>Arthroscopic implantation of InSpace sub-acromial tissue spacer system</description>
    <arm_group_label>InSpace implantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Partial repair of rotator cuff</intervention_name>
    <description>Arthroscopic partial repair of rotator cuff</description>
    <arm_group_label>Tendon Repair</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Positive diagnostic imaging by MRI of the index shoulder indicating a full thickness&#xD;
             Massive Rotator Cuff Tear (MRCT), measuring ≥ 5 cm in diameter involving ≥ two tendons&#xD;
             (confirmed Intra-operatively)&#xD;
&#xD;
          -  Functional deltoid muscle and preserved passive range of motion on physical&#xD;
             examination&#xD;
&#xD;
          -  Documented VAS score of &gt; 30 mm pain&#xD;
&#xD;
          -  Failed non-operative treatment of at least 4 months&#xD;
&#xD;
          -  Patient in general good health,independent, and can comply with all post-operative&#xD;
             evaluations and visits.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to the device material (copolymer of PLA and -ε-caprolactone)&#xD;
&#xD;
          -  Evidence of the following conditions:&#xD;
&#xD;
               1. significant gleno-humeral or acromiohumeral arthritis&#xD;
&#xD;
               2. full thickness cartilage loss as seen on MRI&#xD;
&#xD;
               3. gleno-humeral instability (excessive translation of the humeral head on the&#xD;
                  glenoid fossa)&#xD;
&#xD;
               4. pre-existing deltoid defect or deltoid palsy&#xD;
&#xD;
               5. major joint trauma, infection or necrosis&#xD;
&#xD;
               6. partial thickness tears of the supraspinatous&#xD;
&#xD;
               7. fully reparable rotator cuff tear [Tear of less than 5 cm in diameter (or &lt; 4&#xD;
                  cm2) with retractable tendon that can be fully repaired]&#xD;
&#xD;
          -  The subject requires concomitant subscapularis repair and/or labral repair&#xD;
&#xD;
          -  Previous surgery of the index shoulder in the past 1 year, excluding diagnostic&#xD;
             arthroscopy&#xD;
&#xD;
          -  The subject's condition is bilateral and rotator cuff repair is scheduled or to be&#xD;
             scheduled over the course of this study for the contra lateral shoulder&#xD;
&#xD;
          -  Major medical condition that could affect quality of life and influence the results of&#xD;
             the study (e.g. HIV or other immunosuppressive conditions, active malignancy in the&#xD;
             past 5 years, acute MI, CVA, etc.)&#xD;
&#xD;
          -  Documented evidence of a history of drug/alcohol abuse within 12 months of enrollment&#xD;
&#xD;
          -  The subject's condition represents a worker's compensation case&#xD;
&#xD;
          -  The subject is currently involved in a health-related litigation procedure&#xD;
&#xD;
          -  Females of child-bearing potential who are pregnant or breastfeeding or plan to become&#xD;
             pregnant during the course of the study&#xD;
&#xD;
          -  Concurrent participation in any other investigational clinical study one month prior&#xD;
             to enrollment or during the entire study period&#xD;
&#xD;
          -  The subject has implanted metallic devices (e.g., cardiac pacemakers, insulin pumps,&#xD;
             nerve stimulators), medically implanted clips or other electronically, magnetically or&#xD;
             mechanically activated implants that would contraindicate undergoing a MRI scan or has&#xD;
             claustrophobia that would inhibit ability to undergo a MRI scan .&#xD;
&#xD;
          -  The subject is physically or mentally compromised (e.g., currently being treated for a&#xD;
             psychiatric disorder, senile dementia, Alzheimer's disease, etc.), to the extent that&#xD;
             the Investigator judges the subject to be unable or unlikely to remain compliant to&#xD;
             follow-up&#xD;
&#xD;
          -  The subject is receiving prescription narcotic pain medication for conditions&#xD;
             unrelated to the index shoulder condition&#xD;
&#xD;
          -  The subject currently has an acute infection in the area surrounding the surgical&#xD;
             site.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Assaf Dekel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ortho-Space</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern California Orthopedic Institute</name>
      <address>
        <city>Van Nuys</city>
        <state>California</state>
        <zip>91405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Orthopedics at RUSH</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockford Orthopedic Associates</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>51107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205-1911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Union Memorial Orthopaedics</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Buffalo Buffalo</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>14260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Orthopedics</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati SportsMedicine and Orthopaedic Center - Mercy Health</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Ohio City</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rothman Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Orthopedic Center</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fowler Kennedy Sport Medicine Clinic</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roth McFarlane Hand and Upper Limb Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2015</study_first_posted>
  <results_first_submitted>May 19, 2021</results_first_submitted>
  <results_first_submitted_qc>June 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2021</results_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Massive Rotator Cuff Tear</keyword>
  <keyword>Arthroscopy</keyword>
  <keyword>Shoulder Joint</keyword>
  <keyword>Rotator cuff partial repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotator Cuff Injuries</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT02493660/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT02493660/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects assessed for eligibility n=229</recruitment_details>
      <pre_assignment_details>Subjects excluded (n=45) for various reasons, not meeting criteria (n=11), declined to participate (n=12), and Other (n=22) such as, no medical clearance for surgery, intra-op screen failures, enrollment full.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>InSpace Implantation</title>
          <description>Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation&#xD;
InSpace sub-acromial tissue spacer system: Arthroscopic implantation of InSpace sub-acromial tissue spacer system</description>
        </group>
        <group group_id="P2">
          <title>Tendon Repair</title>
          <description>Arthroscopic partial repair of rotator cuff&#xD;
Partial repair of rotator cuff: Arthroscopic partial repair of rotator cuff</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93">ITT</participants>
                <participants group_id="P2" count="91">ITT</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="90">Investigator requested subject be discontinued prior to any post-procedure efficacy assessments.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Number of subjects who received an InSpace implant and the number of subjects who received a Partial Repair of their rotator cuff.</population>
      <group_list>
        <group group_id="B1">
          <title>InSpace Implantation</title>
          <description>Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation&#xD;
InSpace sub-acromial tissue spacer system: Arthroscopic implantation of InSpace sub-acromial tissue spacer system</description>
        </group>
        <group group_id="B2">
          <title>Tendon Repair</title>
          <description>Arthroscopic partial repair of rotator cuff&#xD;
Partial repair of rotator cuff: Arthroscopic partial repair of rotator cuff</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="183"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.8" spread="7.70"/>
                    <measurement group_id="B2" value="64.7" spread="7.88"/>
                    <measurement group_id="B3" value="65.8" spread="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in the Intent to Treat Population (ITT) With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears (MRCT).</title>
        <description>The primary composite effectiveness endpoint was defined as achievement of the minimal clinically important difference (MCID) improvement for the Western Ontario Rotator Cuff (WORC) score (≥275 points) and American Shoulder and Elbow Society (ASES) score (≥6.4 points) by week 6 and maintenance at month 12 without subsequent secondary surgical intervention (SSSI) or serious adverse device effects (SADEs).&#xD;
The improvement points of Western Ontario Rotator Cuff (WORC) of at least 275 (point scale of 0-2100:lower score is better) and American Shoulder and Elbow Society (ASES) at least 6.4 (point scale of 0-100:higher score is better) reflect the required number of points in improvement for treatment to be considered successful.</description>
        <time_frame>Through to M12 post operation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>InSpace Implantation</title>
            <description>Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation&#xD;
InSpace sub-acromial tissue spacer system: Arthroscopic implantation of InSpace sub-acromial tissue spacer system</description>
          </group>
          <group group_id="O2">
            <title>Tendon Repair</title>
            <description>Arthroscopic partial repair of rotator cuff&#xD;
Partial repair of rotator cuff: Arthroscopic partial repair of rotator cuff</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in the Intent to Treat Population (ITT) With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears (MRCT).</title>
          <description>The primary composite effectiveness endpoint was defined as achievement of the minimal clinically important difference (MCID) improvement for the Western Ontario Rotator Cuff (WORC) score (≥275 points) and American Shoulder and Elbow Society (ASES) score (≥6.4 points) by week 6 and maintenance at month 12 without subsequent secondary surgical intervention (SSSI) or serious adverse device effects (SADEs).&#xD;
The improvement points of Western Ontario Rotator Cuff (WORC) of at least 275 (point scale of 0-2100:lower score is better) and American Shoulder and Elbow Society (ASES) at least 6.4 (point scale of 0-100:higher score is better) reflect the required number of points in improvement for treatment to be considered successful.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1"/>
                    <measurement group_id="O2" value="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was 10% for all composite endpoints. The primary analysis method was a multilinear regression model for Month 12 success with age (&lt;65 years, ≥65 years), gender, and treatment as the model covariates for the PP population for non-inferiority testing.</non_inferiority_desc>
            <p_value>0.0049</p_value>
            <p_value_desc>The non-inferiority threshold was met for the Per Protocol (PP) population.</p_value_desc>
            <method>Multi-linear Regression Model</method>
            <method_desc>Primary analysis method was for Month (M) 12 success with age (&lt;65 years, ≥65 years), gender, and treatment for the Per Protocol (PP) population.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>11</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears From Baseline Through to Month 12 With no SSSIs and no SADEs.</title>
        <description>The secondary composite effectiveness endpoint was defined as achievement of the minimal clinically important difference (MCID) success rates for Western Ontario Rotator Cuff (WORC) total score improvement (≥275) (0-2100:lower score is better) and American Shoulder and Elbow Surgeons (ASES) total score improvement (≥6.4) (0-100:higher score is better) from baseline in the two groups, InSpace and Partial Repair.&#xD;
The Intent to Treat (ITT) population, defined as all randomized subjects with at least one post-treatment effectiveness assessment as randomized, was used as the primary population and to generate all other effectiveness endpoints.</description>
        <time_frame>Through to M12 post operation</time_frame>
        <population>Per Protocol Population (PP) (IS n=88, PR n=88) included all subjects in the ITT population without any major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>InSpace Implantation</title>
            <description>Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation&#xD;
InSpace sub-acromial tissue spacer system: Arthroscopic implantation of InSpace sub-acromial tissue spacer system</description>
          </group>
          <group group_id="O2">
            <title>Tendon Repair</title>
            <description>Arthroscopic partial repair of rotator cuff&#xD;
Partial repair of rotator cuff: Arthroscopic partial repair of rotator cuff</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears From Baseline Through to Month 12 With no SSSIs and no SADEs.</title>
          <description>The secondary composite effectiveness endpoint was defined as achievement of the minimal clinically important difference (MCID) success rates for Western Ontario Rotator Cuff (WORC) total score improvement (≥275) (0-2100:lower score is better) and American Shoulder and Elbow Surgeons (ASES) total score improvement (≥6.4) (0-100:higher score is better) from baseline in the two groups, InSpace and Partial Repair.&#xD;
The Intent to Treat (ITT) population, defined as all randomized subjects with at least one post-treatment effectiveness assessment as randomized, was used as the primary population and to generate all other effectiveness endpoints.</description>
          <population>Per Protocol Population (PP) (IS n=88, PR n=88) included all subjects in the ITT population without any major protocol deviations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6" lower_limit="81.6" upper_limit="95.6"/>
                    <measurement group_id="O2" value="86.4" lower_limit="79.4" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Month 12 in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears.</title>
        <description>The secondary effectiveness endpoint was defined as mean change from baseline to Month 12 for American Shoulder and Elbow Surgeons (ASES) total score improvement (≥ 6.4) (scale of 0-100:higher score is better) from baseline in the two groups, InSpace and Partial Repair.</description>
        <time_frame>Through to M12 post operation</time_frame>
        <population>Per Protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>InSpace Implantation</title>
            <description>Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation&#xD;
InSpace sub-acromial tissue spacer system: Arthroscopic implantation of InSpace sub-acromial tissue spacer system</description>
          </group>
          <group group_id="O2">
            <title>Tendon Repair</title>
            <description>Arthroscopic partial repair of rotator cuff&#xD;
Partial repair of rotator cuff: Arthroscopic partial repair of rotator cuff</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Month 12 in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears.</title>
          <description>The secondary effectiveness endpoint was defined as mean change from baseline to Month 12 for American Shoulder and Elbow Surgeons (ASES) total score improvement (≥ 6.4) (scale of 0-100:higher score is better) from baseline in the two groups, InSpace and Partial Repair.</description>
          <population>Per Protocol population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.38" lower_limit="37.01" upper_limit="45.75"/>
                    <measurement group_id="O2" value="40.95" lower_limit="36.81" upper_limit="45.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Month 12 in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears Through to Month 12.</title>
        <description>The secondary effectiveness endpoint was defined as mean change from baseline to Month 12 for Western Ontario Rotator Cuff (WORC) total score improvement (≥275) (scale of 0-2100:lower score is better) in the two groups, InSpace and Partial Repair.</description>
        <time_frame>Through to M12 post operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>InSpace Implantation</title>
            <description>Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation&#xD;
InSpace sub-acromial tissue spacer system: Arthroscopic implantation of InSpace sub-acromial tissue spacer system</description>
          </group>
          <group group_id="O2">
            <title>Tendon Repair</title>
            <description>Arthroscopic partial repair of rotator cuff&#xD;
Partial repair of rotator cuff: Arthroscopic partial repair of rotator cuff</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Month 12 in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears Through to Month 12.</title>
          <description>The secondary effectiveness endpoint was defined as mean change from baseline to Month 12 for Western Ontario Rotator Cuff (WORC) total score improvement (≥275) (scale of 0-2100:lower score is better) in the two groups, InSpace and Partial Repair.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1015.58" lower_limit="-1116.52" upper_limit="-914.63"/>
                    <measurement group_id="O2" value="-937.99" lower_limit="-1042.85" upper_limit="-833.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Month 12 in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears From Baseline Through to Month 12.</title>
        <description>The secondary effectiveness endpoint was defined as change from baseline to Month 12 for Constant-Murley (CS) Shoulder Outcome score (scale of 0-100:higher score better) in the two groups, InSpace and Partial Repair.</description>
        <time_frame>Through to M12 post operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>InSpace Implantation</title>
            <description>Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation&#xD;
InSpace sub-acromial tissue spacer system: Arthroscopic implantation of InSpace sub-acromial tissue spacer system</description>
          </group>
          <group group_id="O2">
            <title>Tendon Repair</title>
            <description>Arthroscopic partial repair of rotator cuff&#xD;
Partial repair of rotator cuff: Arthroscopic partial repair of rotator cuff</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Month 12 in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears From Baseline Through to Month 12.</title>
          <description>The secondary effectiveness endpoint was defined as change from baseline to Month 12 for Constant-Murley (CS) Shoulder Outcome score (scale of 0-100:higher score better) in the two groups, InSpace and Partial Repair.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.70" lower_limit="22.59" upper_limit="30.81"/>
                    <measurement group_id="O2" value="23.51" lower_limit="19.73" upper_limit="27.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change From Baseline for the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears From Baseline Through to Month 12.</title>
        <description>The secondary effectiveness endpoint was defined as change in baseline to Month 12 for Quality of Life (EQ-5D-5L) (scale of 0-100: lower score better) in the two groups, InSpace and Partial Repair.</description>
        <time_frame>Through to M12 post operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>InSpace Implantation</title>
            <description>Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation&#xD;
InSpace sub-acromial tissue spacer system: Arthroscopic implantation of InSpace sub-acromial tissue spacer system</description>
          </group>
          <group group_id="O2">
            <title>Tendon Repair</title>
            <description>Arthroscopic partial repair of rotator cuff&#xD;
Partial repair of rotator cuff: Arthroscopic partial repair of rotator cuff</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Change From Baseline for the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears From Baseline Through to Month 12.</title>
          <description>The secondary effectiveness endpoint was defined as change in baseline to Month 12 for Quality of Life (EQ-5D-5L) (scale of 0-100: lower score better) in the two groups, InSpace and Partial Repair.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.36" lower_limit="-5.05" upper_limit="-3.66"/>
                    <measurement group_id="O2" value="-3.93" lower_limit="-4.56" upper_limit="-3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears Through to Month 12.</title>
        <description>The secondary effectiveness endpoint was defined as the mean change from baseline at Month 12 for Visual Analogue Scale (VAS) (scale of 0-100:lower score is better) in the two groups, InSpace and Partial Repair.</description>
        <time_frame>Through to M12 post operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>InSpace Implantation</title>
            <description>Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation&#xD;
InSpace sub-acromial tissue spacer system: Arthroscopic implantation of InSpace sub-acromial tissue spacer system</description>
          </group>
          <group group_id="O2">
            <title>Tendon Repair</title>
            <description>Arthroscopic partial repair of rotator cuff&#xD;
Partial repair of rotator cuff: Arthroscopic partial repair of rotator cuff</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears Through to Month 12.</title>
          <description>The secondary effectiveness endpoint was defined as the mean change from baseline at Month 12 for Visual Analogue Scale (VAS) (scale of 0-100:lower score is better) in the two groups, InSpace and Partial Repair.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.18" lower_limit="-61.12" upper_limit="-51.25"/>
                    <measurement group_id="O2" value="-52.24" lower_limit="-57.71" upper_limit="-46.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears Through to Month 12.</title>
        <description>The secondary effectiveness endpoint was defined as mean change from baseline at Month 12 for American Shoulder and Elbow Surgeons (ASES) range of motion (ROM)-physician reported portion. (scale of 0-180 Degrees: higher score is better) in the two groups, InSpace and Partial Repair.</description>
        <time_frame>Through to M12 post operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>InSpace Implantation</title>
            <description>Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation&#xD;
InSpace sub-acromial tissue spacer system: Arthroscopic implantation of InSpace sub-acromial tissue spacer system</description>
          </group>
          <group group_id="O2">
            <title>Tendon Repair</title>
            <description>Arthroscopic partial repair of rotator cuff&#xD;
Partial repair of rotator cuff: Arthroscopic partial repair of rotator cuff</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Per Protocol Population With Surgical Treatment Success of the InSpace Device as a Primary Surgical Treatment for Full-thickness Massive Rotator Cuff Tears Through to Month 12.</title>
          <description>The secondary effectiveness endpoint was defined as mean change from baseline at Month 12 for American Shoulder and Elbow Surgeons (ASES) range of motion (ROM)-physician reported portion. (scale of 0-180 Degrees: higher score is better) in the two groups, InSpace and Partial Repair.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.29" lower_limit="27.00" upper_limit="43.58"/>
                    <measurement group_id="O2" value="19.52" lower_limit="11.75" upper_limit="27.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collected over 12 months and 24 months visit.</time_frame>
      <desc>The All-Cause Mortality, Serious Adverse Event, and Adverse events are listed for the safety population and some subjects reported more than one AE or SAE.</desc>
      <group_list>
        <group group_id="E1">
          <title>InSpace Implantation</title>
          <description>Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation&#xD;
InSpace sub-acromial tissue spacer system: Arthroscopic implantation of InSpace sub-acromial tissue spacer system</description>
        </group>
        <group group_id="E2">
          <title>Tendon Repair</title>
          <description>Arthroscopic partial repair of rotator cuff&#xD;
Partial repair of rotator cuff: Arthroscopic partial repair of rotator cuff</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>System Organ Class</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>eg. Multi-vessel Coronary Artery Disease</sub_title>
                <description>Same subject can have more than one event.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Angina Pectoris (Chest pain-Cardiac)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <description>Same subject can have more than one event.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <description>Same subject can have more than one event.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>eg. Gastrointestinal haemorrhage, short-bowel syndrome, small intestinal obstruction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>eg. Event leading to Death, non-cardiac chest pain, surgical failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>eg. Pain or inflammation</sub_title>
                <description>All body areas reported</description>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>eg.Prostate cancer, leukemia, Parathyroid tumor</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>eg. dizziness, Aphasia, Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>eg.Laryngeal granuloma, Chronic obstructive pulmonary disease, pulmonary mass</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>System Organ Class</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Note: Some subjects may have more than one event.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Pre-Ventricular Contractions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Local swelling</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UTI, Bronchitis, pneumonia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="93"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall and injury, meniscus injury, Tendon rupture (anywhere in body)</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="93"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain, Arthralgia, back pain (anywhere in body)</sub_title>
                <description>Note: One subject may have more than one event in all of these categories.</description>
                <counts group_id="E1" events="96" subjects_affected="51" subjects_at_risk="93"/>
                <counts group_id="E2" events="71" subjects_affected="48" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache, dizziness</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of 45 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and can only extend the embargo with patent protection review.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heather Neill, VP Clinical Operations</name_or_title>
      <organization>OrthoSpace Ltd.</organization>
      <phone>615-483-7438</phone>
      <email>heather.neill@stryker.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

